Latest on Pharmaceutical Industry


Lundbeck to buy Parkinson's drug developer in potential $1.1 billion deal

Lundbeck agreed to buy Prexton Therapeutics, a specialist in treatments for brain disorders, in a deal potentially worth $1.1 billion, the Danish drugmaker said on Friday. Prexton has drug candidate foliglurax in phas..Read More...

Ionis and Akcea Partner to Commercialize Inotersen for hATTR

Ionis Pharmaceuticals and Akcea Therapeutics, Inc., an affiliate of Ionis, today announced an exclusive, worldwide license by Ionis to Akcea for inotersen and AKCEA-TTR-LRx, formerly IONIS-TTR-LRx, in a transaction poten..Read More...




Granada, Spain,


Pharmaceutics & Novel Drug Delivery Systems 2018

Golden Tulip Berlin,
Conferenceseries Ltd

Press Releases

Intezyne Partners with Exosome Diagnostics on IT-139 Companion Diagnostic

Intezyne a clinicalstage biopharmaceutical company developing novel anticancer therapies announced that it has partnered with Exosome Diagnostics a privately held company focused on developing and commercializing revolut.. Read More...

Tetra Discovery Partners Announces FDA Clearance of IND for Phase 2 Trial of BPN14770 in Fragile X Syndrome

Tetra Discovery Partners Inc today announced that the US Food and Drug Administration has accepted the Investigational New Drug Application IND for BPN14770 a novel selective small molecule inhibitor of the phosphodieste.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics